Moreover, research has shown that approximately 15% of FLT3-ITD-mutated AML patients exhibit recurrent MLL3 mutations or gene deletions, and patients with MLL3 mutations generally have a poor prognosis148. This evidence concerns the gene KMT2C and acute myeloid leukemia.